Status:

TERMINATED

A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma

Lead Sponsor:

M.D. Anderson Cancer Center

Conditions:

Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

Eligibility:

All Genders

18+ years

Phase:

EARLY_PHASE1

Brief Summary

We propose a focused, prospective pilot clinical imaging trial to evaluate 11C-Gln PET/CT followed by 18F-FSPG PET/CT in 20 HNSCC patients. Imaging metrics that are common to PET (e.g. SUVmax, peak or...

Detailed Description

Primary Objective: The primary objective of this trial is to evaluate the ability of 11C-Gln and 18F-FSPG PET imaging to detect tumors in patients with HNSCC. Hypotheses: 11C-Gln PET and 18F-FSPG PE...

Eligibility Criteria

Inclusion

  • ≥18 years of age;
  • Pathologically or cytologically confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC);
  • Documented results from (or scheduled to undergo) CT or MRI as a SOC procedure within 42 days prior to baseline investigational 11C-Gln PET/CT and 18F-FSPG PET/CT;
  • Measurable disease by RECIST v1.1 defined as tumor lesions with a longest diameter ≥ 10 mm and/or malignant lymph nodes with a short axis diameter ≥ 15 mm.
  • Ability to provide written informed consent in accordance with institutional policies.
  • Non-English speaking subject will be included. Verbal Translation Preparative Sheet (VTPS) short form will be utilized in consent non-English speaking subject

Exclusion

  • Body weight ≥400 pounds or body habitus or disability that will not permit the imaging protocol to be performed;
  • Pregnant or lactating females.
  • Have an allergy to intravenous contrast
  • eGFR\<30

Key Trial Info

Start Date :

September 14 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 7 2025

Estimated Enrollment :

3 Patients enrolled

Trial Details

Trial ID

NCT05322135

Start Date

September 14 2022

End Date

March 7 2025

Last Update

April 9 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

M D Anderson Cancer Center

Houston, Texas, United States, 77030